Different roles of IL-15 from IL-2 in differentiation and activation of human CD3+CD56+ NKT-like cells from cord blood in long term culture.
The abundantly available source of stem cells and the low incidence of graft-versus-host disease (GVHD) made cord blood an attractive alternative source of hematopoietic stem cells for transplantation. Besides T cell and NK cell, NKT cell played an important role in low incidence of GVHD during allogeneic transplantation. IL-2 and IL-15 can stimulate T cell and NK cell proliferation, survival and activation in vitro. But they exhibited different effects on the GVHD during allogeneic transplantation. In this study, we explored the different effects of exogenous IL-2 and IL-15 on the expansion of CD3+CD56+ NKT-like cells by in vitro long term culture of cord blood mononuclear cells (CBMCs). The results showed that CD3+CD56+ NKT-like cells were derived from CD34-CD56- CBMCs and IL-2 improved CD3+CD56+ NKT-like cell expansion more strongly than IL-15. Interestingly, CD3+CD56+ NKT-like cells from IL-15-cocultured CBMCs had significantly lower apoptotic frequency and higher levels of activation markers (CD161, CD25, and IFN-gamma) than those from IL-2-cocultured CBMCs. The anti-apoptotic and activating effects of IL-15 on CD3+CD56+ NKT-like cells from CBMCs might possibly explain the pathogenic role of IL-15 in GVHD during allogeneic transplantation.
Wang
Yanyan
Y
Institute of Immunology, Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, 443 Huangshan Road, Hefei, Anhui 230027, China.
Zheng
Xiaodong
X
Wei
Haiming
H
Sun
Rui
R
Tian
Zhigang
Z
D017209:Apoptosis; D002454:Cell Differentiation; D002478:Cells, Cultured; D005312:Fetal Blood / Q000166:cytology* / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D019409:Interleukin-15 / Q000494:pharmacology / Q000502:physiology*; D007376:Interleukin-2 / Q000494:pharmacology / Q000502:physiology*; D015847:Interleukin-4 / Q000378:metabolism; D008213:Lymphocyte Activation; D038041:Lymphopoiesis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D015854:Up-Regulation; D051020:bcl-X Protein / Q000378:metabolism
C494811:BCL2L1 protein, human; D019409:Interleukin-15; D007376:Interleukin-2; D019253:Proto-Oncogene Proteins c-bcl-2; D051020:bcl-X Protein; D015847:Interleukin-4; D007371:Interferon-gamma